Testing a new lupus drug for safety and early effects
Part of Immune system & allergy, Skin clinical trials.
This study tests a new injectable drug, HC022, for people with lupus or cutaneous lupus. It aims to see if the drug is safe, tolerable, and begins to work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with lupus (SLE) or cutaneous lupus (CLE).
- You must be 18 years or older.
- You cannot have active severe kidney or brain lupus.
- You cannot have other autoimmune diseases (like rheumatoid arthritis or scleroderma).
- You must not have a serious or recent infection, like tuberculosis or hepatitis.
- You must be willing to use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
This trial tests a new drug called 626 for people with systemic lupus erythematosus (SLE). It aims to see if the drug is safe and effective at reducing disease activity.
This study tests a new experimental drug called SCTC21C in people with systemic lupus erythematosus (SLE), an autoimmune disease where the body attacks its own tissues. The trial aims to see if this drug can help reduce lupus symptoms and inflammation when added to standard treatments.
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
This study tests an investigational drug called SAR448501/DR-0201 in people with active lupus or rheumatoid arthritis who have not responded well to standard treatments. The goal is to see if the drug is safe and helps control disease activity.
This study tests a single dose of a new drug called SHR-7012 in healthy volunteers to check if it is safe and how the body handles it. It is a first-in-human trial, so participants will be closely monitored.
Hear when a new Cutaneous Lupus Erythematosus (CLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.